We narrowed to 9 results for: Mycs

1. pENN.AAV.CAG.Flex.GFPsm_myc.WPRE.SV40 (AAV1)

   Viral Prep

   #98927-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pENN.AAV.CAG.Flex.GFPsm_myc.WPRE.SV40 (#98927). In addition to the viral particles, you will also receive purified pENN.AAV.CAG.Flex.GFPsm_myc.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent expression of GFPsm_myc spaghetti monster construct. Spaghetti monster constructs are not fluorescent ("dark") to allow full range of antibody staining. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Loren Looger

   Article

   Viswanathan et al Nat Methods. 2015 Jun;12(6):568-76. doi:

   Promoter

   CAG

   Tags

   GFPsm-myc (spaghetti monster construct)

   Available since

   June 12, 2018

   Availability

   Academic Institutions and Nonprofits only

2. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV1)

   Viral Prep

   #87306-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   April 18, 2019

   Availability

   Academic Institutions and Nonprofits only

3. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV9)

   Viral Prep

   #87306-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   Jan. 26, 2021

   Availability

   Academic Institutions and Nonprofits only

4. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV2)

   Viral Prep

   #87306-AAV2

   Purpose

   Ready-to-use AAV2 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   Aug. 24, 2020

   Availability

   Academic Institutions and Nonprofits only

5. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV8)

   Viral Prep

   #87306-AAV8

   Purpose

   Ready-to-use AAV8 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   Jan. 26, 2021

   Availability

   Academic Institutions and Nonprofits only

6. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV5)

   Viral Prep

   #87306-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   July 22, 2020

   Availability

   Academic Institutions and Nonprofits only

7. AAV pEF1a-DIO-FLPo-WPRE-hGHpA (AAV Retrograde)

   Viral Prep

   #87306-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Li Zhang

   Article

   Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

   Promoter

   EF1a

   Tags

   None

   Available since

   July 22, 2020

   Availability

   Academic Institutions and Nonprofits only

8. AAV phSyn1(S)-FlpO-bGHpA (AAV Retrograde)

   Viral Prep

   #51669-AAVrg

   Purpose

   Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-FlpO-bGHpA (#51669). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-FlpO-bGHpA plasmid DNA. hSyn-driven FlpO expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Hongkui Zeng

   Article

   Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

   Promoter

   Syn

   Tags

   None

   Available since

   Oct. 28, 2021

   Availability

   Academic Institutions and Nonprofits only

9. pLenti CMV GFP Hygro (656-4) (Lentiviral Prep)

   Viral Prep

   #17446-LV

   Purpose

   Ready-to-use Lentiviral Prep particles produced from pLenti CMV GFP Hygro (656-4) (#17446). In addition to the viral particles, you will also receive purified pLenti CMV GFP Hygro (656-4) plasmid DNA. Lentiviral particles carrying the GFP and hygromycin resistance.

   Depositor

   Eric Campeau, Paul Kaufman

   Article

   Campeau et al PLoS One. 2009 Aug 6;4(8):e6529.

   Promoter

   Tags

   None

   Available since

   Oct. 6, 2020

   Availability

   Academic Institutions and Nonprofits only